DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-19.64%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$240M
AUM Growth
+$240M
(-18%)
Cap. Flow
+$17.4M
Cap. Flow
% of AUM
7.27%
Top 10 Holdings %
Top 10 Hldgs %
50.22%
Holding
91
New
10
Increased
29
Reduced
12
Closed
11
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$6.13M |
| 2 |
Compugen
CGEN
|
$4.36M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$3.39M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$3.24M |
| 5 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
$2.63M |
Top Sells
| 1 |
ARQL
Arqule Inc
ARQL
|
$9.94M |
| 2 |
Cytokinetics
CYTK
|
$4.44M |
| 3 |
VYNE Therapeutics
VYNE
|
$3.7M |
| 4 |
AtriCure
ATRC
|
$2.65M |
| 5 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$2.65M |
Sector Composition
| 1 | Healthcare | 91.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $41.3M | 17.24% | 13,680,554 | – | – |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $13.3M | 5.57% | 228,089 +104,871 | +85% | +$6.13M |
|
3
Fate Therapeutics
FATE
$120M
| $10.4M | 4.36% | 470,000 | – | – |
|
4
Galapagos
GLPG
$2.07B
| $9.09M | 3.79% | 46,375 -625 | -1% | -$122K |
|
5
DexCom
DXCM
$29.5B
| $8.98M | 3.75% | 33,338 -3,000 | -8% | -$808K |
|
|
6
AtriCure
ATRC
$1.84B
| $8.05M | 3.36% | 239,729 -79,000 | -25% | -$2.65M |
|
7
iShares Biotechnology ETF
IBB
$5.6B
| $7.85M | 3.28% | 72,900 +8,000 | +12% | +$862K |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.55M | 3.15% | 179,642 +80,700 | +82% | +$3.39M |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $6.94M | 2.9% | 80,208 +19,200 | +31% | +$1.66M |
|
10
ProQR Therapeutics
PRQR
$237M
| $6.79M | 2.83% | 1,237,400 +123,400 | +11% | +$677K |
|
11
Akebia Therapeutics
AKBA
$833M
| $6.47M | 2.7% | 853,538 +83,000 | +11% | +$629K |
|
|
LMNX
12
DELISTED
Luminex Corp
LMNX
| $5.62M | 2.34% | 204,091 | – | – |
|
|
TVRD
13
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $4.9M | 2.05% | 371,033 +42,500 | +13% | +$561K |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $4.75M | 1.98% | 165,306 +40,500 | +32% | +$1.16M |
|
|
15
Compugen
CGEN
$132M
| $4.36M | 1.82% | +600,000 | New | +$4.36M |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.96M | 1.65% | 293,440 +25,601 | +10% | +$346K |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $3.93M | 1.64% | 346,535 +97,681 | +39% | +$1.11M |
|
18
Corbus Pharmaceuticals
CRBP
$115M
| $3.92M | 1.63% | 747,300 +450,000 | +151% | +$2.36M |
|
|
AGTC
19
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $3.81M | 1.59% | 1,160,878 +801,688 | +223% | +$2.63M |
|
20
Ascendis Pharma
ASND
$11.8B
| $3.8M | 1.59% | 33,737 +5,637 | +20% | +$635K |
|
21
Alector
ALEC
$238M
| $3.74M | 1.56% | 155,000 +10,000 | +7% | +$241K |
|
|
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
| $3.54M | 1.48% | 143,249 +36,500 | +34% | +$903K |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.24M | 1.35% | +42,102 | New | +$3.24M |
|
|
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.08M | 1.29% | 90,600 +15,900 | +21% | +$541K |
|
25
Kura Oncology
KURA
$686M
| $3.06M | 1.28% | 307,541 +134,066 | +77% | +$1.33M |
|